|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Declaration of Interests Register | | | | | | | |
| TA Committee D Publication Date: 05/06/2019 | | | | | | | |
| Topic: Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210] | | | | | | | |
| Name | Role with NICE | Type of interest | Description of interest | Relevant dates | | | Comments |
| Interest  arose | Interest  declared | Interest  ceased |
| *Dr Samreen Ahmed* | *Clinical Expert* | *Personal non-direct interest* | *Dr Ahmed has been on the advisory committee board for Roche* |  |  |  | It was agreed that this declaration would not prevent Dr Ahmed from participating in this section of the meeting |
| *Gary Middleton* | *Clinical Expert* | *Financial direct interest* | *Received travel and reimbursement from the Company, Roche* |  |  |  | *It was agreed that this declaration would not prevent Gary Middleton from participating in this section of the meeting.* |
| *Carol Davies* | *Patient Expert* | *None* | *N/A* |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |